| Monique Mcgee, LCSW | |
|
175 Gwinnett Dr, Lawrenceville, GA 30046-8444 | |
| (678) 209-2394 | |
| Not Available |
| Full Name | Monique Mcgee |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 12 Years |
| Location | 175 Gwinnett Dr, Lawrenceville, Georgia |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104284389 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Helping Hearts Behavioral Health Services Llc | 1052724440 | 4 |
News Archive
ICON plc,, today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.
Hospitalized children go home sooner and are less likely to be readmitted when the hospital has an antibiotic stewardship program that's dedicated to controlling antibiotic prescriptions and treatment, according to a study being presented at IDWeek 2014-. The study is the first to show the benefits of such programs on children's health.
The Foundation for Innovative New Diagnostics (FIND) announced today the launch of a request for proposals (RFP) to accelerate the development, manufacturing, and market availability of accurate, affordable, quality-assured and easy-to-use SARS-CoV-2 self-tests for use in low- and middle-income countries (LMICs).
An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies.
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 3 days ago
| Entity Name | Helping Hearts Behavioral Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578170882 PECOS PAC ID: 1052724440 Enrollment ID: O20210104000019 |
News Archive
ICON plc,, today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.
Hospitalized children go home sooner and are less likely to be readmitted when the hospital has an antibiotic stewardship program that's dedicated to controlling antibiotic prescriptions and treatment, according to a study being presented at IDWeek 2014-. The study is the first to show the benefits of such programs on children's health.
The Foundation for Innovative New Diagnostics (FIND) announced today the launch of a request for proposals (RFP) to accelerate the development, manufacturing, and market availability of accurate, affordable, quality-assured and easy-to-use SARS-CoV-2 self-tests for use in low- and middle-income countries (LMICs).
An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies.
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Monique Mcgee, LCSW 175 Gwinnett Dr, Lawrenceville, GA 30046-8444 Ph: (678) 209-2394 | Monique Mcgee, LCSW 175 Gwinnett Dr, Lawrenceville, GA 30046-8444 Ph: (678) 209-2394 |
News Archive
ICON plc,, today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.
Hospitalized children go home sooner and are less likely to be readmitted when the hospital has an antibiotic stewardship program that's dedicated to controlling antibiotic prescriptions and treatment, according to a study being presented at IDWeek 2014-. The study is the first to show the benefits of such programs on children's health.
The Foundation for Innovative New Diagnostics (FIND) announced today the launch of a request for proposals (RFP) to accelerate the development, manufacturing, and market availability of accurate, affordable, quality-assured and easy-to-use SARS-CoV-2 self-tests for use in low- and middle-income countries (LMICs).
An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies.
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 3 days ago
Miss Opal Hope Minott, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1083 Simonton Hill Ct, Lawrenceville, GA 30045 Phone: 770-375-0479 Fax: 678-985-4228 | |
Ms. Tomekia Holandia Raines, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 270 W Oak St Ste 2, Lawrenceville, GA 30046 Phone: 770-866-1060 | |
Akisha Miller, Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 888 Legacy Park Dr Ste 301, Lawrenceville, GA 30043 Phone: 855-284-7483 Fax: 617-807-0958 | |
Natali Nelson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1760 Lakes Pkwy Unit 4416, Lawrenceville, GA 30043 Phone: 413-427-3627 | |
Ms. Jasmine Denise Williams, MSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 2229 Oakland Downs Way, Lawrenceville, GA 30044 Phone: 850-524-9069 | |
Ms. Jacklyn J Montero, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 175 Gwinnett Dr, Lawrenceville, GA 30045 Phone: 770-339-5377 Fax: 770-339-5016 | |
Gail S Hammond, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 295 S Culver St Ste A, Lawrenceville, GA 30046 Phone: 770-217-7903 Fax: 770-995-0171 |